FridaySep 23, 2022 10:30 am

Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs

Endometriosis is a disorder that causes the tissue that lines the inside of the uterus to grow outside the reproductive organ. It is associated with menstrual irregularities and pain and is estimated to affect around 10% of American women of reproductive age. The condition develops into endometrial cancer when the endometrial cells grow out of control, leading to the development of a tumor. Unfortunately, there is no cure for endometriosis, and current treatments can only do so much to ease the condition’s symptoms so they don’t interfere with an individual’s day-to-day activities. Prior studies have found that patients with endometrial…

Continue Reading

ThursdaySep 22, 2022 12:38 pm

New Research Finds Thinning Retina May Signal Onset of Alzheimer’s

Alzheimer’s is a progressive neurological disease that causes brain cells to shrink and die. It is characterized by memory problems, visual-spatial issues and impaired judgment. The Centers for Disease  Control and Prevention (CDC) estimates that around 5.8 million Americans have Alzheimer’s disease and similar dementias. Although there is no cure for Alzheimer’s disease, early diagnosis of the neurological condition can allow for treatment and a better quality of life. Researchers have long theorized that eyes, specifically the retina, can act as a window into the brain and allow physicians to diagnose Alzheimer’s during the early stages. Backed by a growing…

Continue Reading

WednesdaySep 21, 2022 2:16 pm

Study Finds Using Social Media May Negatively Affect Youths’ Mental Health

In 2004, Mark Zuckerberg launched Facebook, and within days, some 600 students had created their accounts on the social platform. Today, the number of users on the platform stands at 2.93 billion. Researchers theorize that the expansion of this social platform may have affected the mental well-being of youth. This is backed by CDC data, showing that between 2000 and 2007, the suicide rate among individuals aged between 10 and 24 was stable. However, in the period between 2007 and 2017, the rate increased by 57%. Given this trend, it is important to understand the relationship between the use of…

Continue Reading

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

Continue Reading

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric…

Continue Reading

TuesdaySep 20, 2022 11:07 am

Scientists Discover Unexpected Way in Which Air Pollution Causes Cancer

Scientists have for the longest time believed that cancer begins to develop when cells in the body acquire more mutations and multiply at an abnormal rate. However, new research has shed light on how air pollution can cause cancer, a discovery that could completely change the understanding of how tumors develop. This study, which was conducted by scientists at the Francis Crick Institute in London, found that air pollution was awakening old damaged cells in the body instead of damaging healthy cells. The investigators, who are also based at University College London, were focused on finding what could trigger the…

Continue Reading

TuesdaySep 20, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere In September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch products In August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI platform technology used to detect and diagnose heart attacks On November 15, 2021, HeartBeam had its IPO on the Nasdaq under ticker symbol ‘BEAT’ The company’s management team has significant experience in software…

Continue Reading

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year The current standard of care for GBM is ineffective for approximately 60% of patients Initial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the…

Continue Reading

MondaySep 19, 2022 10:42 am

New Study Finds Hypertension Accelerates Bone Aging

A new study has found that high blood pressure (hypertension) may accelerate bone aging, as observed in mice models. The research was presented during this year’s Hypertension Scientific Sessions conference, hosted by the American Heart Association. The researchers’ objective was to understand how high blood pressure contributed to osteoporosis and help find ways to decrease the risk of the bone disease and better protect individuals from experiencing fragility fractures later in life. For their study, the researchers examined inflammation linked to hypertension in mice. This led to the discovery that high blood pressure may be linked to osteoporosis. Hypertension and…

Continue Reading

FridaySep 16, 2022 2:17 pm

The US Reaches One Million Organ Transplants

Last week, the United States clocked one million organ transplants. This historic milestone was confirmed by the United Network for Organ Sharing at 12.50 p.m. ET. This private nonprofit organization is in charge of managing the sole organ transplantation and procurement network in the United States, under contract with the federal government. Details about the patient who received this millionth organ are unknown. Additionally, it is unclear what organ brought the number to one million. The first successful organ transplant was carried out decades ago, in 1954. It was conducted at Boston’s Brigham and Women’s Hospital by Dr. Joseph Murray.…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000